Novartis Investigative Site

Almada 2805-267

1 studies enrolling now · 11 studies all time

What they study most

Acute Myocardial Infarction, Ankylosing Spondylitis, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Healthy Volunteers, Pulmonary Arterial Hypertension, Hidradenitis Suppurativa, Non-radiographic Spondyloarthritis, Primary Prevention of Atherosclerotic Cardiovascular Disease, Primary Sjogren Syndrome, Sjögren Syndrome, Spondylitis, Ankylosing, Type 2 Diabetes Mellitus

Studies at this site

• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) — Running, not enrolling
• Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome — Completed
• Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS) — Completed
• Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis — Completed
• 16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early